pharmaceutical company ABV Inc. is looking for its next hit.
Now its blockbuster immune-disease therapy Humira facing low price competitionAbbVie is turning to a pair of next-generation successors to recoup the billions of dollars in sales it will lose, chief executive officer richard gonzalez Said. It’s also betting on four drug approvals By the end of next year.